An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
VERDICT
The label
Markup
read at $52.64
Scholar Rock Holding Corporation holds its Markup at $52.64.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-06
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 390 days
Price
$52.64
Valuation
N/A trailing · -22.21 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.67
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$52.64
N/A P/E · -22.21 fwd
Our fair value
$58.00
10% discount
Analyst target (avg)
$58.00
+10% to current
Target low $48.00Analyst target rangeTarget high $70.00
▲ current $52.64 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$52.64
you are here
Conservative
$48.00
-9%
Analyst avg
$58.00
+10%
Our fair value
$58.00
+10%
Analyst high
$70.00
+33%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Profit margin
0.00%
Debt to equity
74.52
Analyst consensus
Strong Buy · 16 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its accounts receivable. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 26.9% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 10.9% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 80.7% of assets, above the 49% limit.Fail
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Rare disease biotech missing the numbers that matter
A family facing spinal muscular atrophy needs real treatments, not just hope. Scholar Rock works on molecular mechanisms that could ease neuromuscular diseases, with analysts clustered around a $58 target and our own fair value sitting only 10 percent higher than the current $52.86 price.
We pass. The ethical screen returns insufficient data because basic financial ratios are absent, and the available figures, forward P/E of minus 22.3 times, zero profit margin and return on equity of minus 139 percent, leave too many gaps for a clear verdict. Unknown moat adds to the uncertainty.
Those gaps matter in a sector where most candidates fail late trials and cash burn can stretch for years. Without reliable ratios the margin of safety stays untested, regardless of bullish consensus. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
SRRK trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (16 analysts) rates it none, with a mean price target of $59. Entered 2026-08-13 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-08-13Markup · changed$52.64+19.1%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (16 analysts) rates it none, with a mean price target of $59.
2026-07-18Accumulation$44.18+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (16 analysts) rates it none, with a mean price target of $59.
2026-07-03Accumulation$44.18+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$44.18Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$48.35
-8.8%
·
$912
-8.8%
2 months
$49.96
-11.8%
·
$883
-11.8%
3 months
$41.80
+5.5%
·
$1,055
+5.5%
6 months
$46.83
-5.9%
·
$942
-5.9%
1 year
$34.42
+28.1%
·
$1,281
+28.1%
2 years
$9.63
+357.8%
·
$4,578
+357.8%
3 years
$7.00
+529.9%
·
$6,299
+529.9%
5 years
$31.64
+39.4%
·
$1,394
+39.4%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever SRRK does next, these words stay.
Scholar Rock Holding Corporation · SRRK · Markup · $52.64
Recorded 2026-08-06 · before the outcome · scored mechanically
